Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
Open accessThe DOI matches its Crossref record; 129 of the 137 references it cites were found in a registry or an index; 14 of the 57 sources its claims cite were checked for support.
Abstract
BACKGROUND: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) led us to review controlled trials of treatments aimed at preventing early relapses or later recurrences in adults diagnosed with MDD to summarize available data and to guide further research. METHODS: Reports (n = 97) were identified through systematic, computerized literature searching up to February 2015. Treatment versus control outcomes were summarized by random-effects meta-analyses. RESULTS: In 45 reports of 72 trials (n = 14 450 subjects) lasting 33.4 weeks, antidepressants were more effective than placebos in preventing relapses (response rates [RR] = 1.90, confidence interval [CI]: 1.73-2.08; NNT = 4.4; p < 0.0001). In 35 reports of 37 trials (n = 7253) lasting 27.0 months, antidepressants were effective in preventing recurrences (RR = 2.03, CI 1.80-2.28; NNT = 3.8; p < 0.0001), with minor differences among drug types. In 17 reports of 22 trials (n = 1 969) lasting 23.7 months, psychosocial interventions yielded inconsistent or inconclusive results. CONCLUSIONS: Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies (pharmacological and psychological) conducted over longer times, as well as identifying clinical predictors of positive or unfavorable responses and of intolerability of long-term treatments in MDD.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants significantly reduce relapse and recurrence in adults with major depressive disorder compared with placebo, with long-term maintenance treatment showing the largest pooled effect. Psychosocial interventions yielded inconsistent and generally weaker evidence, though some benefit appeared in patients with multiple prior episodes.
Key findings
- In 45 reports of 72 continuation trials (n = 14,450; mean 8.35 months), antidepressants were more effective than placebo in preventing relapse: RR = 1.90 (95% CI 1.73–2.08), NNT = 4.4 (3.8–5.2), p < 0.0001; relapse risk averaged 23.3% with continued antidepressant vs 49.4% after discontinuation.
- In 35 reports of 37 long-term trials (n = 7,253; mean 26.8 months), antidepressants were effective in preventing recurrence: RR = 2.03 (95% CI 1.80–2.28), NNT = 3.8 (3.3–4.6), p < 0.0001; 32/37 (86.5%) trials showed significant superiority of active drug over control.
- In 17 reports of 22 psychosocial trials (n = 1,969; mean 23.7 months), pooled RR = 1.39 (95% CI 1.13–1.70), NNT = 6.0 (3.8–14), p = 0.002, but 11/22 (50.0%) comparisons were nonsignificant; benefit was greater in patients with high prior recurrences (RR = 1.63, 95% CI 1.04–2.57) than low prior recurrences (RR = 0.80, 95% CI 0.58–1.09).
- Meta-regression found longer initial treatment before randomization was associated with larger drug–placebo contrast in continuation trials (β = +0.048, CI 0.024–0.073, p < 0.001), and longer long-term treatment duration was associated with larger drug–placebo contrast in maintenance trials (β = +0.104, CI 0.044–0.163, p < 0.001).
Methods
- Systematic review and random-effects meta-analysis of controlled trials identified through computerized searches of PubMed/Medline, Scieverse, SciDirect, and Web-of-Science up to February 2015; 803 reports screened, 146 reviewed in detail, and 97 reports included.
- Inclusion required adults with major depressive disorder, English-language reports, and examination of relapse or recurrence with pharmacological or non-pharmacological treatment; exclusions were bipolar depression, seasonal depression, juvenile depression, and studies only of adverse events or costs.
- Two investigators independently extracted data; analyses computed relative response rates (RRs), rate differences, and number-needed-to-treat (NNT), with meta-regression testing covariates including trial year, size, age, sex proportion, prior episodes, initial treatment weeks, trial duration, and antidepressant type.
Limitations
- Stated by the paper: few well-designed non-pharmacological or combination-treatment studies; follow-up periods ranged from several months to five years (average up to 2 years), with actual times to new episodes usually not reported; many trials used “enriched” designs requiring short-term response, limiting generalizability; many trials discontinued active treatment in barely recovered patients, possibly contributing to inferior placebo outcomes; juvenile and mainly geriatric depression were excluded; some placebo arms were reused in multi-arm trials, though sensitivity analyses showed minor effects; and many studies lacked clinical details on prior episodes, subjective wellness, functioning, and predictors of tolerability or response.
- Evident from the text: psychosocial trials were heterogeneous and half of comparisons were nonsignificant, making conclusions about psychosocial maintenance treatment less secure than those for antidepressants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Findings from random-effects meta-analysis of 37 controlled, long-term trials (>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 [CI: 1.80-2.28]) is highly significant (z-score = 11.7, p < 0.0001).](https://figures.cochat.ai/paper-figures/aeb112a55a4446f3aa7a4372000f0d00/prevention-of-relapse-and-recurrence-in-adults-with-major-depressive-disorder-figure-2.jpg)
Verification
Claims the paper makes
10 Valid · 1 Not valid · 20 Not checked · 55 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Their findings favored ECT added or compared with medicinal treatments (Gagne et al., 2000; Kellner et al., 2006).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Gagne et al., 2000 matched to “Efficacy of Continuation ECT and Antidepressant Drugs Compared to Long-Term Antidepressants Alone in Depressed Patients” (2000) source
- Disputedcites Kellner et al., 2006 matched to “Continuation Electroconvulsive Therapy vs Pharmacotherapy for Relapse Prevention in Major Depression: A Multisite Study From the Consortium for Research in Electroconvulsive Therapy (CORE)” (2006) sourceExperimental — accuracy not yet measured
The EFFICACY RESULTS section (page not provided) reports no statistically significant difference between continuation ECT and pharmacotherapy; relapse was 37.1% with ECT versus 31.6% with pharmacotherapy. The COMMENT section likewise says there was no statistical evidence that either treatment had greater efficacy. This study therefore does not support a finding favoring ECT over medication. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Family psychoeducation appeared to be useful long-term in two studies reported from Japan (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion
What the sources say
- Supportedcites Shimazu et al., 2011 matched to “Family psychoeducation for major depression: randomised controlled trial” (2011) source
The Method section identifies this as a study conducted in Japan. The Discussion reports that family psychoeducation significantly reduced relapse of major depression for up to nine months, supporting its usefulness over the study’s follow-up period. This citation accounts for one of the two studies named in the citing sentence. (LLM, conf=0.91)
- Partly supportedcites Shimodera et al., 2012 matched to “Cost-effectiveness of family psychoeducation to prevent relapse in major depression: Results from a randomized controlled trial” (2012) sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes section reports fewer relapses and more relapse-free days with family psychoeducation during nine months of follow-up in this Japanese trial. But the Discussion explicitly says whether its preventive effect lasts beyond nine months is unknown, so the source does not establish long-term usefulness. This verdict addresses Shimodera et al. only, not the other study cited in the sentence; our copy provides no page numbers. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These failed trials involved antidepressants such as tricyclic antidepressants (Maj et al., 1992), SSRIs (Wilson et al., 2003; Reynolds et al., 2006), the anxiolytic SNRI milnacipran (Rouillon et al., 2000), and a preparation of the plant Hypericum perforatum (St. John’s Wort; Kasper et al., 2008).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Long-Term Antidepressant Treatment
What the sources say
- Not matchedcites Maj et al., 1992
An author–year citation the paper’s reference list doesn’t settle. We don’t search these by name.
- Supportedcites Wilson et al., 2003 matched to “Older community residents with depression: long-term treatment with sertraline: Randomised, double-blind, placebo-controlled study” (2003) source
The citation to Wilson et al. (2003) is attached to the SSRI example, not to the other drug classes or the count of five trials. In “Analysis of recurrence” (page unavailable), the paper reports no significant difference between sertraline and placebo in preventing recurrence during maintenance treatment. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites Reynolds et al., 2006 matched to “Maintenance Treatment of Major Depression in Old Age” (2006) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Partly supportedcites Shimazu et al., 2011 matched to “Family psychoeducation for major depression: randomised controlled trial” (2011) sourceExperimental — accuracy not yet measured
The Discussion reports that four sessions of family psychoeducation significantly reduced relapse compared with treatment as usual, supporting clinical effectiveness. But the Family psychoeducation section says sessions occurred every two weeks, and the Discussion reports outcomes for up to 9 months; the intervention did not continue for up to 10 months. (LLM, conf=0.90)
- Partly supportedcites Shimodera et al., 2012 matched to “Cost-effectiveness of family psychoeducation to prevent relapse in major depression: Results from a randomized controlled trial” (2012) sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes report fewer relapses with family psychoeducation than with treatment as usual over nine months (2 versus 15). But Methods > Procedure describes four sessions held every two weeks, not psychoeducation continued for up to 10 months; nine months was the follow-up period. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Kuyken et al., 2008 matched to “Mindfulness-based cognitive therapy to prevent relapse in recurrent depression.” (2008) source
- Partly supportedcites Bondolfi et al., 2010 matched to “Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: Replication and extension in the Swiss health care system” (2010) sourceExperimental — accuracy not yet measured
The Results report similar relapse rates over 14 months for MBCT plus treatment as usual and treatment as usual alone (29% versus 34% in the intention-to-treat sample), supporting the claim that this trial did not show fewer recurrences. But relapse occurred significantly later among MBCT participants who relapsed, so the unqualified statement that it provided no superior protection omits a benefit the paper reports. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Mathew et al., 2010 matched to “The long-term effects of mindfulness-based cognitive therapy as a relapse prevention treatment for major depressive disorder” (2010) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
51 more claims · 3 with their cited sources checked
Create a free account to see all 86 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sim et al. included various types of maintenance therapy such as antidepressant monotherapy, polypharmacy, combination therapy (e.g., antidepressants plus psychotherapy, electroconvulsive therapy, and lithium) regardless of whether a study continued the same antidepressant used for acute treatment in the maintenance phase or switched to a new one.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, a meta-analysis by Sim et al. showed that 6 of the 15 studies submitted to the FDA by Borges et al. had the same number of subjects as the other published studies included in their meta-analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, they used the data from Borges et al.’s study which risks the possibility of duplicate analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in agreement with clinical studies showing that remitted patients treated with fluoxetine present higher rates of relapse, in comparison with other ADs.30, 31”
From Adult hippocampal neuroplasticity triggers susceptibility to recurrent depression (2017) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most trials recruited patients with depression from specialist mental health services, treated them with antidepressants for 3 to 8 months, and randomly assigned patients who had a response to therapy to continue antidepressant therapy or switch to placebo.”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [9]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“(z=11.7, p < .0001”
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“z = 11.7, p < .0001”
- Consistentz = 3.15reported p = .002 · recomputed p = .002
“(z = 3.15, p = .002”
- Consistentz = 2.14reported p = .03 · recomputed p = .032
“z = 2.14, p = .03”
- Consistentz = 1.41reported p = .16 · recomputed p = .159
“z = 1.41, p = .16”
2 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“Ma & Teasdale, 2004 a | 38 | MCT (high) | TAU | 0.98 (0.68–1.26)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“1.4 (1.1–1.9)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“Only TCAs (n = 10) and the pool of SSRIs (n = 11) and SNRIs (n = 7) provided at least 10 trials for meta-analysis, and all yielded similar RR values (2.09, 2.10, and 2.17, respectively).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“SSRIs (2.17) ≥ SNRIs (2.10) ≥ TCAs (2.09)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“b, long-term antidepressants (2.02) > a, continuation of antidepressants (1.90) > c, long-term psychosocial treatments (1.39)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“| RR (95% CI) | 1.90 (1.73–2.08) | 2.03 (1.80-2.28) | 1.39 (1.13–1.70) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Per trial | 189 (138–239) | 188 (131–245) | 124 (92.1–156) |”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
Reported 189 · recomputed 200.694444
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“Montgomery et al., 1998 | Mirtazapine | 387 | 6.78 (3.32–13.9) | 4.2 (5.9–6.8) | 1.04”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“5.9–6.8”
Citations
Cites
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M., & Lau, M. A. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.615 · Cited by 3,236 · cited 4×
“, 2010), and others found beneficial effects among patients with at least three previous depressive episodes (Teasdale et al., 2000; Ma and Teasdale, 2004).”
BackgroundInfluentialMa, S. H., & Teasdale, J. D. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.1.31 · Cited by 1,390 · cited 10×
“Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression (Montgomery et al., 1993; Teasdale et al., 2000; Lepine et al., 2004; Ma and Teasdale, 2004; Kelin et al., 2010).”
BackgroundInfluentialThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodMindfulness-based cognitive therapy to prevent relapse in recurrent depression.
Kuyken, W., Byford, S., Taylor, R. S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013786 · Cited by 770 · cited 2×
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
BackgroundPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735 · cited 2×
“There is also some evidence that use of CBT during an index episode of acute depression may have long-lasting beneficial effects in limiting risks of relapse or recurrences for up to 2 years after initial remission (Hollon et al., 2005; Dobson et al., 2008).”
BackgroundSackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686
Reynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Research works printed but not linked: 3
- Georgotas, 1985, Affective disorders: pharmacotherapy, Compr Psychiatry, 4, 821
- 10.1176/appi.ajp.131.2.186 · doi:10.1176/appi.ajp.131.2.186
- Lendresse, 1985, Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels, Psychiatrie Francaise, 16, 156
Cited by
Items 101–200 of 219
Molecular Imaging of Depressive Disorders
Ruhé, H. G., Visser, A. K. D., Frøkjær, V. G., Haarman, B. C. M., Klein, H. C., & Booij, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-40384-2_5 · Cited by 13
Durgam, S., Chen, C., Migliore, R., Prakash, C., & Thase, M. E. (2019) · Depression and Anxiety · doi:10.1002/da.22872 · Cited by 11
“Meta-analyses of relapse-prevention studies demonstrated that longer initial and continuation treatment resulted in lower rates of relapse for antidepressants compared with placebo (Geddes et al., 2003; Glue et al., 2010; Sim et al., 2015).”
ResultZhou, D., Zhou, X., Lin, Q., Wang, W., Lv, Z., Chen, X., Nie, G., & Kuang, L. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.025 · Cited by 15
Zhou, J.-J., Wang, X., Yang, J., Zhu, X.-Q., Xiao, L., Feng, L., & Wang, G. (2022) · Trials · doi:10.1186/s13063-022-06295-9 · Cited by 10
“However, a substantial proportion of patients with MDD experience disease relapse or recurrence (R/R), within 10 years after the first depressive episode; rates of recurrence have been reported to be as high as 85% [15, 16].”
BackgroundMelnyk, B. M. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000152 · Cited by 14
“31 Relapse is likely to occur if the root cause of the depression is a negative or un-helpful pattern of thinking and cognitive-behavioral are not learned and practiced.”
BackgroundPouchon, A., Nasserdine, R., Dondé, C., Bertrand, A., Polosan, M., & Bioulac, S. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2224920 · Cited by 12
Molenaar, N. M., Brouwer, M. E., Kamperman, A. M., Burger, H., Williams, A. D., Hoogendijk, W. J. G., Bockting, C., & den Berg, M. P. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212964 · Cited by 12
“Outside of the perinatal period, antidepressants seem to be more protective than placebos in preventing recurrences, although this effect is not uniform [36] and recent trials have demonstrated tapering of antidepressants is safe when preventive cognitive therapy is provided [37, 38].”
ResultBenzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression
Shiwaku, H., Fujita, M., & Takahashi, H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061938 · Cited by 10
Hypersomnolence is associated with non-remission of major depressive disorder
Cheung, M. M. S., Lam, S. P., Chau, S. W. H., Chan, N. Y., Li, T. M. H., Wing, Y. K., & Chan, J. W. Y. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.04.018 · Cited by 10
Kitay, B. M., Murphy, E., Macaluso, M., Corlett, P. R., Hershenberg, R., Joormann, J., Martinez‐Kaigi, V., Nikayin, S., Rhee, T. G., Sanacora, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115585 · Cited by 13
The development and tendency of depression researches: Viewed from the microbiota-gut-brain axis
Liang, S., Wu, X., Xu, H., Niu, Y., & Jin, F. (2018) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972017-01182 · Cited by 9
Zavorotnyy, M., Ehrlich, F., & Nenadić, I. (2020) · PsyCh Journal · doi:10.1002/pchj.355 · Cited by 11
Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management
Törnblom, H., & Drossman, D. A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_106 · Cited by 9
Mental Well-being in Menopause
Green, R., Metcalf, C. A., & Santoro, N. F. (2024) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2024.10.002 · Cited by 9
López-Moríñigo, J.-D., Boldrini, M., Ricca, V., Oquendo, M. A., & Baca‐García, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143057 · Cited by 9
Gut microbiota and postpartum depression: a Mendelian randomization study
Zhang, J., Wei, L., Tan, H., & Pang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1282742 · Cited by 14
“Nearly 20% of patients with depression relapse within 20 years of their initial onset, and most people develop suicidal thoughts, with 4% -5% dying from depression-related suicide (3, 4).”
BackgroundSuicidal Risks in Reports of Long-Term Treatment Trials for Major Depressive Disorder: Table 1.
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv107 · Cited by 9
“In our recent review and meta-analyses of reports of long-term trials of treatments for major depressive disorder patients, we noted that remarkably little potentially relevant and interesting clinical information was included in most reports (Sim et al., 2015).”
InfluentialSelf-citationKumagai, N., Tajika, A., Hasegawa, A., Kawanishi, N., Fujita, H., Tsujino, N., Jinnin, R., Uchida, M., Okamoto, Y., Akechi, T., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113919 · Cited by 8
Schuling, R., Huijbers, M. J., van Ravesteijn, H., Kuyken, W., & Speckens, A. E. M. (2021) · Mindfulness · doi:10.1007/s12671-021-01675-9 · Cited by 10
“In a study examining up to 15 years of prospective follow-up data on the course of MDD, Hardeveld et al.”
BackgroundInfluentialSchienle, A., & Jurinec, N. (2021) · Psychology Research and Behavior Management · doi:10.2147/prbm.s294940 · Cited by 9
Microbiome‐gut‐brain axis as a novel hotspot in depression
Ma, Y., Xu, P., Bai, Z., & Fang, J. (2024) · Brain‐X · doi:10.1002/brx2.43 · Cited by 11
Differing antidepressant maintenance methodologies
Safer, D. J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.021 · Cited by 9
McIntyre, R. S., Sundararajan, K., Behl, S., Hefting, N., Jin, N., Brewer, C., Hobart, M., & Thase, M. E. (2024) · Acta Neuropsychiatrica · doi:10.1017/neu.2024.32 · Cited by 9
“However, relapse rates following remission are high (Sim et al ., 2016), and long-term studies show that most patients in recovery will eventually experience a recurrence of depressive symptoms (Mueller et al ., 1999; Solomon et al ., 2000).”
InfluentialCost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar
Abushanab, D., Mohammed, S., Abdellatif, R., Al‐Muftah, W., Ismail, S. I., Hail, M. A., Al-Marridi, W. Z., Abdallah, O., Al‐Khuzaei, N., Althani, A., et al. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2410197 · Cited by 7
“…published studies on CYP2D6 and CYP2C19 genetic testing in patients with MDD (Carta et al., 2022; Fabbri et al., 2021; Shams et al., 2006; Sim. et al., 2015; Sluiter et al., 2019), a 6-week decision-ana-lytic simulation model was developed to assess the use of PGx-guided testing for…”
MethodElectroacupuncture prevents depression via PINK1/Parkin-driven suppression of NLRP3 activation
Li, Z., Huang, J., Zhang, J., Tian, B., Guo, Y., Zhou, X., Mao, X., Wang, Z., Tian, F., Gou, C., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111609 · Cited by 6
Stenmark, L., Kellner, C. H., Landén, M., Larsson, I., Msghina, M., & Nordenskjöld, A. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13373 · Cited by 8
van Kasteren, Y., Strobel, J., Bastiampillai, T., Linedale, E., & Bidargaddi, N. (2022) · JMIR Human Factors · doi:10.2196/35403 · Cited by 6
“Psychotropic medications, including antipsychotics, antidepressants, and mood stabilizers, are routinely used in the treatment of severe mental illness such as schizophrenia and bipolar disorder [6-8].”
Predicting recurrence of depression using cardiac complexity in individuals tapering antidepressants
George, S. V., Kunkels, Y. K., Smit, A. C., Wichers, M., Snippe, E., van Roon, A. M., & Riese, H. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02474-7 · Cited by 9
Judging Mental Health Disorders Using Decision Tree Models
Roy, S., Aithal, P. S., & Bose, R. (2021) · International Journal of Health Sciences and Pharmacy · doi:10.47992/ijhsp.2581.6411.0058 · Cited by 9
“We can do it either via an amalgamation of treatments [15, 16] or doctor may refer to antidepressant treatment [17, 18] and psychological treatment [19, 20].”
BackgroundLi, X., Yin, X., Guan, Z., Qian, Y., & Loux, T. M. (2025) · Public Health · doi:10.1016/j.puhe.2025.03.001 · Cited by 11
Hamina, A., Pinzón-Espinosa, J., Taipale, H. T., Schneider‐Thoma, J., Radua, J., Efthimiou, O., Cardoner, N., Correll, C. U., Fusar‐Poli, P., Mittendorfer-Rutz, E., et al. (2026) · World Psychiatry · doi:10.1002/wps.70013 · Cited by 5
“Maintenance treatment with antidepressants can effectively reduce the risk of early relapse and later recurrence rates compared to placebo 9-11 , with a number needed to treat to prevent one recurrence of approximately 3.8 9,12 .”
InfluentialFeixas, G., Moggia, D., Niño‐Robles, N., Aguilera, M., Montesano, A., & Salla, M. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00122-w · Cited by 8
A pharmacopsychometric overview of major depressive episodes in positive psychiatry
Bech, P., Vernooij-Dassen, M. J. F. J., Moniz-Cook, E. D., & Jeon, Y. (2018) · International Psychogeriatrics · doi:10.1017/s1041610217003015 · Cited by 5
“The whole duration of the maintenance phase is found to correspond to the duration of an episode of major depression, i.e. 12 months (Sim et al., 2016).”
BackgroundEvolutionary Perspectives on Depression
Rantala, M. J., & Luoto, S. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009030564.010 · Cited by 11
Thorpe, D., Strobel, J. E., & Bidargaddi, N. P. (2023) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-022-02091-2 · Cited by 5
“Medications are often an essential component of plans to reduce the risk of relapse for many people diagnosed with complex mental illnesses; as such, they are core parts of lives of many people living with schizophrenia [3, 8], bipolar disorder [9, 10], and major depressive disorder [11].”
BackgroundUnmet Needs in Psychiatry: Bipolar Depression
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_4 · Cited by 8
Self-citationBockting, C., Breedvelt, J., & Brouwer, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00224-7 · Cited by 6
An update on pharmacotherapy for recurrent depression in 2022
Belge, J.-B., Sabbe, A. C. F., & Sabbe, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2223962 · Cited by 7
“tain short-term clinical responses is advocated for preventing recurrence in depression [20], the evidence supporting this strat-”
BackgroundHallford, D. J., Rusanov, D., Yeow, J., et al. (2021) · doi:10.31234/osf.io/s276e · Cited by 5
Reich, H., Schreynemackers, S., Amin, R., Ludwig, S., Zippelius, J., Leimhofer, J., Dunker, T., Schriewer, E., Carell, A., Weber, Y. G., et al. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101492 · Cited by 4
“The highly recurring nature of depression and its devastating consequences for patients, their families, and the society makes the monitoring and prolonged disease management of depression an increasingly recognized priority [7].”
Atkins, R., Kelly, T.-A., Linz, S. J., Jackson, K. J., Pontes, M., Wunnenberg, M., Williams, K., Stellmacher, T., Lewis, H., Halty, N.-D., et al. (2021) · Western Journal of Nursing Research · doi:10.1177/01939459211037042 · Cited by 5
“It is also possible that some mothers may have been clinically depressed and experiencing exacerbations/relapses that are characteristic of clinical depression (Buckman et al., 2018; Sim et al., 2015).”
BackgroundCan Quetiapine Prolong the Antidepressant Effect of Ketamine? A 5-Year Follow-up Study
Amiaz, R., Saporta, R., Noy, A., Berkenstadt, H., & Weiser, M. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001489 · Cited by 4
“Copyright © 2021 Wolters Kluwer For that reason, relapse prevention in patients who initially responded to ketamine infusion is a therapeutic challenge.(15) Several researchers recommend the use of maintenance ketamine treatments of intravenous or intranasal ketamine to preserve remission.”
BackgroundHuang, J., Cai, Y., Zhang, M., Xu, X., Su, Y., Zhu, N., Jin, F., Fang, Y., & Peng, D. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.103 · Cited by 5
A guide to what works for depression: An evidence-based review
Morgan, A. J., Reavley, N. J., Jorm, A. F., Bassilios, B., Hopwood, M., Allen, N. B., & Purcell, R. (2019) · Cited by 5
Pérez, V., Martínez-Navarro, R., Pérez‐Aranda, A., Martínez-Sadurní, L., Arranz-Estévez, F. J., Colom, F., Pujol, J., Toll, A., Iniesta-Terré, M., & Elices, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.095 · Cited by 4
Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., & Miklowitz, D. J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0018 · Cited by 7
“23 The negative beliefs of depressed individuals can become fixed, which, for some, makes CBT difficult to engage with or ineffective.”
Aggestrup, A. S., Martiny, F., Faurholt‐Jepsen, M., Hvenegaard, M., Christensen, R., Davidsen, A. S., & Martiny, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291559 · Cited by 4
Алексеевич, Г. С., Ivanova, S. А., & Bokhan, N. A. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112105140 · Cited by 4
Chen, Z., Dou, Z., Hui, X., Wang, Z., Zeng, S., Yang, X., Takahashi, E., Popovic, M. R., Wang, L., & Li, W. (2022) · Brain Sciences · doi:10.3390/brainsci13010038 · Cited by 3
“Despite the progress in clinical treatment, the risk of relapse is still high, with an estimated recurrence rate of higher than 50% [2].”
BackgroundStress sensitivity in women with a history of recurrent versus first-episode major depression
Gan, A. K. X., & Gibb, B. E. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116382 · Cited by 3
Watanabe, K., Thase, M. E., Kikuchi, T., Tsuboi, T., Asami, Y., Pappadopulos, E. A., Zhang, M., Boucher, M., & Kornstein, S. G. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000183 · Cited by 3
“Clinical trials have consistently shown that longterm treatment with antidepressant drugs significantly reduces the risk of relapse or recurrence of major depression compared with placebo (Borges et al., 2014; Sim et al., 2015).”
BackgroundRisk factors and prevention of recurrent dynamics of depression
Veltishchev, D. Y., Kovalevskaya, O. B., & Seravina, O. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711761120-125 · Cited by 3
Berwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · Biological Psychiatry · doi:10.1101/2020.01.28.922500 · Cited by 3
Hallford, D. J., Austin, D., Takano, K., Fuller‐Tyszkiewicz, M., & Raes, F. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8yadm · Cited by 3
Abu-Ashour, W., Delaney, S., Farrell, A., Gamble, J., Hawboldt, J., & Sale, J. E. M. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251322401 · Cited by 5
Riiser, S., Smith‐Sivertsen, T., Baste, V., Haukenes, I., Hetlevik, Ø., & Ruths, S. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02825-x · Cited by 2
“The evidence supporting the protective role of psychological treat-ment has been inconsistent and inconclusive [10], and even fewer studies have investigated combinations of treatment measures typically provided in primary care [10].”
InfluentialPompili, M., Berardelli, I., Sarubbi, S., Rogante, E., Cifrodelli, M., Erbuto, D., Lamis, D. A., & Baldessarini, R. J. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.70002 · Cited by 3
Self-citationObieche, O., Tan, J.-Y. B., Sharma, S., Bressington, D. T., & Wang, T. (2025) · Nursing Reports · doi:10.3390/nursrep15100364 · Cited by 2
“Even so, research indicates high rates of nonadherence to antidepressant treatment [68,69], despite evidence supporting its efficacy [70] and effectiveness [71] compared to placebos.”
The Effect of Psychiatric History on Pain and Related Outcomes Among Living Kidney Donors
Fox, K. R., Gulin, S. L., Bruschwein, H. M., Rose, T. L., Burker, E. J., Kozłowski, T., & Loiselle, M. M. (2021) · Progress in Transplantation · doi:10.1177/15269248211002809 · Cited by 2
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_4 · Cited by 3
Phillips, J. L., Blier, P., & Talbot, J. D. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100613 · Cited by 6
Aggestrup, A. S., Martiny, F., Henriksen, L., Davidsen, A. S., & Martiny, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302229 · Cited by 2
Prescripción prolongada de antidepresivos en atención primaria. Impacto en la salud pública
Madueño, A., Berro-Ramírez, G., Chávez-Gata, L., Torrescusa-Camisón, R., Climent‐Rodríguez, J. A., Navarro‐Abal, Y., & Gómez-Salgado, J. C. (2025) · Atención Primaria · doi:10.1016/j.aprim.2025.103234 · Cited by 3
Li, K., Tang, S.-X., Tao, Y.-F., He, H., Ma, M., Zhang, Q.-Q., Huang, M., Chen, W., Liang, H. W., Deng, A., et al. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i6.105555 · Cited by 8
Aggestrup, A. S., Martiny, K., & Davidsen, A. S. (2025) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2025.2530628 · Cited by 2
Suicidal Risks in Report of Reports of Long-Term Treatment Trials for Major Depressive Disorder
Dardennes, R. M., Anbar, N. A., Divac, S. M., et al. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw084 · Cited by 2
Li, K., Tao, J., Li, Y., Chen, M., Wu, X., Liao, Y., Lin, X., & Gan, Z. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s160767 · Cited by 2
“Treatment with medication, so far, is still the most effective method to cure and prevent MDE from recurring or becoming chronic.(1,2) Therefore, treatment guidelines recommend a continuation of treatment after an initial response for 4–9 months and maintenance treatment of 2 years or longer in the case of recurrent m…”
Erim, D. (2020) · Value in Health · doi:10.1016/j.jval.2020.09.008 · Cited by 3
Case-based learning: safe withdrawal and tapering of antidepressants
(2023) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2023.1.196471 · Cited by 2
Psychopharmacology for Pediatric Depressive Disorders
Rengasamy, M. L., Shalev, A., & Birmaher, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_16 · Cited by 2
Moore, M., Lau, M. A., Haigh, E. A. P., et al. (2022) · doi:10.31231/osf.io/mx32f · Cited by 2
A Computational Theory of Mindfulness Based Cognitive Therapy from the “Bayesian Brain” PerspectivePreprint
Manjaly, Z., & Iglesias, S. (2019) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/qu5gb · Cited by 2
Predicting recurrence of depression using cardiac complexity in individuals tapering antidepressantsPreprint
George, S. V., Kunkels, Y. K., Smit, A. C., et al. (2022) · doi:10.31234/osf.io/gk8rd · Cited by 2
Ormel, J., & Emmelkamp, P. M. G. (2025) · Verhaltenstherapie · doi:10.1159/000542334 · Cited by 1
“Zweitens blieb das Rückfall-/Rezidivrisiko signi fi kant, obwohl es durch fort-gesetzte Medikation oder präventive Psychotherapie erheblich reduziert wurde [48, 54].”
Family Psychoeducation for Major Depressive Disorder: A Systematic Review
Obieche, O., Tan, J. (., Sharma, S., Bressington, D. T., Wang, T., & Li, M. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70205 · Cited by 2
Elad, D., Story, G. W., Berwian, I. M., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03402-5 · Cited by 2
“Randomized controlled trials indicate that continual maintenance treatment with antidepressant medication reduces the risk of relapse or recurrence [5 – 8].”
Randomized Controlled Trials and the Efficacy of Psychotropic Medications
Dunlop, B. W., & Ribeiro, C. M. D. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-56015-1_4-1 · Cited by 2
Leis, Á., Ronzano, F., Mayer, M. Á., Furlong, L. I., & Sanz, F. (2020) · Journal of Medical Internet Research · doi:10.2196/20920 · Cited by 4
“They are commonly used as first-line treatment for depression [21-23] and are usually prescribed as maintenance therapy to prevent relapse [4,23-26].”
BackgroundMo, J., Qinlong, X., Li, J., Zhaoxing, C., Ma, X., Qihua, Z., & He, G. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230418104418 · Cited by 2
Kargar, S. T., Vakili, F., Peivandi, S., Jahanfar, S., Elyasi, F., & Hamzehgardeshi, Z. (2024) · BMC Psychology · doi:10.1186/s40359-024-01796-5 · Cited by 2
“Major depression is a recurrent disorder, and in the general population, it increases the likelihood of subsequent episodes [35].”
BackgroundSuicide in psychiatric disorders: rates, risk factors, and therapeutics
Tondo, L., & Baldessarini, R. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00004-6 · Cited by 1
Self-citationPsychopharmacotherapy of Depressive Disorders
Kavakbasi, E., & Baune, B. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_427 · Cited by 1
studies, O. T. R. N. C. E. S. C. I. C., device, A. S. P. A. E. I. C. S. U. T. R. P. R. C. D. P. I. (. A. W. A. D. D., sensors, I. I. P. T. U. E. A. V. O. D. T. S. D. T. B. T. C. B. O. B. I. T. T. O. D. W. T. C. S. B. E. T. C. W. A. V. O. C. O. (., data, W. A. A. T. I. S. C. P. B. W. O. L. T., capsule, I. F. T. P. T., profile, I. F., instrumentation, O. O. I. T. A. C. O. S. C. E. T. E. A. T. I., studies, W. T. D. I. D. F. L. I. C., usage, R. A. S. I. I. T. L. O. U. D. C. I. I. A. C. T. T. Q. D. C. P. I. C. O. A., studies, P. I. W. D. O. C. B. D. F. D. E., et al. (2020) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2020.ab01.abstracts · Cited by 1
Lahouaoula, I., Li, V. W., Scott, A., Do, A., Michalak, E. E., Murphy, J., Huang, S., & Lam, R. W. M. (2021) · medRxiv · doi:10.1101/2021.09.29.21264324 · Cited by 1
“Several meta-analyses of randomized controlled trials (RCTs) have confirmed that maintenance antidepressants are effective in preventing relapse [3-5].”
Ma, Y., Xu, P., Luo, Y., Sun, J., Guo, C., & fang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1759648/v1 · Cited by 1
Aggestrup, A. S., Martiny, F., Faurholt‐Jepsen, M., Hvenegaard, M., Christensen, R., Davidsen, A. S., & Martiny, K. (2022) · medRxiv · doi:10.1101/2022.10.06.22280499 · Cited by 1
Elad, D., Story, G. W., Berwian, I. M., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2024) · doi:10.31234/osf.io/5buq4 · Cited by 1
The Construction of Happiness in Depression
Alcaraz, M. O., & Medina, J. C. (2018) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Kang, C., Yuan, J., Li, X., Wei, Y., Fan, X., Rohlof, H., Zhou, F., Zhang, Y., & Yang, J. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3578799
A Novel Combined Treatment for Relapse Prevention of Depression: A Case Report
Khayyer, Z., Sabaghypour, S., Amini, B., & Shojaei, A. (2020) · Middle East Journal of Rehabilitation and Health Studies · doi:10.5812/mejrh.105005
“Besides, many patients experience relapses following receiving acute treatment (20).”
BackgroundInfluentialBARREIRA HEMATOENCEFÁLICA, EIXO GASTROINTESTINAL-SNC E INFECÇÃO PELO SARS-COV2
Arnholdt, A. C. V. (2021) · doi:10.22533/at.ed.30721041111
A PESSOA COM DEFICIÊNCIA VISUAL NO CONTEXTO DA PANDEMIA DO COVID-19
Figueiredo, E. L. A., Brandolin, F., Oliveira, I. J. D. A. S., Figueiredo, J. R. M., de Oliveira, J. T. M., & Abade, M. L. (2021) · doi:10.22533/at.ed.30721041115
PRÁXIS DA FISIOTERAPIA NA SINDEMIA POR COVID-19: CONTEXTUALIZAÇÃO E PROGNOSE
Pereira, C. M. D. S., Oliveira, I. J. D. A. S., de Oliveira, J. T. M., Fraga, M. C., de Lima, R. P., Ribeiro, S. D. S., & de Souza, M. F. (2021) · doi:10.22533/at.ed.30721041114
FATORES GENÉTICOS E EPIGENÉTICOS RELACIONADOS À COVID-19
Colete, C. C. F. A., Martins, L. M., & Mangiavacchi, P. M. (2021) · doi:10.22533/at.ed.3072104112
Curcio, F. S., da Costa, H. M. V., Rangel, T. L. V., Mangiavacchi, B. M., & Dellatorre, R. D. S. Z. (2021) · doi:10.22533/at.ed.3072104119
Nunes, C. D. R., Curcio, F. S., & Borges, T. R. B. (2021) · doi:10.22533/at.ed.3072104115
Rangel, T. L. V., Curcio, F. S., & da Costa, H. M. V. (2021) · doi:10.22533/at.ed.3072104114
Challenges of Mood Disorders Care
(2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18202
Psychopharmacotherapy of Depressive Disorders
Kavakbasi, E., & Baune, B. T. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_427-1
Metadata
- Authors
- Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sim, Kang
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-07
- Volume
- 19
- Issue
- 2
- Pages
- pyv076
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772815
- OpenAlex
- W1913659607
- Semantic Scholar
- cbb9e5ab88cd7ec19a0140daf20022efa2e38311
- Cited by
- 218
- References
- 137
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 38 · 2020: 34 · 2019: 20 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Bruce J. Anderson Foundation
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- major depressive disorder, relapse prevention, recurrence prevention, antidepressants, psychosocial interventions, long-term treatment, predictors of treatment response, residual depressive symptoms
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Major Depressive Disorder, Humans, Psychotherapy, Recurrence, Controlled Clinical Trials as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.